tirzepatide shortage fda update 🚨 Alert: No Longer on FDA's Drug List As of October 2, 2024, the has announced that the Tirzepatide shortage has been resolved. This means that all doses of Important Notice: Tirzepatide Compounding Update

Patients who succeed post-discontinuation typically have established consistent exercise routines (150+ minutes per week), protein-forward meal planning, structured meal timing, and ongoing accountability

Contraindications Tirzepatide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as well as those with a known allergy to the medication

Semaglutide currently has broader availability through compounding pharmacies and more insurance coverage options

If your phone has a timer function, set it after each injection

Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, is a dual GIP and GLP-1 receptor agonist that affects how your body regulates blood sugar and processes food

Hypertension, atherosclerosis, endothelial dysfunction, atrial fibrillation, sleep apnea, and vascular inflammation can all influence cognitive risk